Abstract
Podocalyxin is a negatively charged protein located in the kidney podocyte membrane, which is a glycosylated cell surface sialomucin of the CD34 family. It is the main component of the glomerular basement membrane charge barrier and has an important role in the regulation of glomerular filtration barrier permeability. There is an argument on the association of PCX with diabetic renal complications and its probability to be a new marker for early diagnosis of diabetic renal complications. The aim of the study was determination of urinary podocalyxin levels in T2DM patients and to analyze its correlation with albumin to creatinine ratio and glycemic control. By consecutive sampling, 82 samples were selected and divided into two groups. The control group consisted of 20 healthy subjects, and the case group was 62 subjects with T2DM. Albumin creatinine ratio, serum creatinine, glycemic control, body mass index and urinary podocalyxin were measured for both groups. Significant higher levels of urinary podocalyxin were found in the case group compared to the control group (p =0.005). There was a significant difference in urinary podocalyxin levels between case groups (normoalbuminuria, microalbuminuria, and macroalbuminuria) (p<0.001). Urinary podocalyxin levels had a significant strong positive correlation with albumin creatinine ratio (p<0.001), and weak positive correlation with serum creatinine and HbA1c. Due to significant differences in urinary podocalyxin levels between the case and control group and within case groups, as well as its positive correlation with albumin creatinine ratio, it might be a good marker for the diagnosis of diabetic kidney disease.
References
Akankwasa, G., Jianhua, L., Guixue, C., Changjuan, A., Xiaosong, Q. (2018). Urine markers of podocyte dysfunction: a review of podocalyxin and nephrin in selected glomerular diseases. Biomarkers in Medicine, 12(8), 927-935.?
Alicic, R.Z., Rooney, M.T., Tuttle, K.R. (2017). Diabetic Kidney Disease. Clin J Am Soc Nephrol, 12(12), 2032–2045.
Azhari, F., Novadian, Effendi, I., Ali, Z., Suprapti, Anggraini, R.M.D., Kusnadi, Y., Shahab, A. (2023) “The Role of Podocyte Cells in Diabetic Nephropathy: A Narrative Literature Review”, Bioscientia Medicina: Journal of Biomedicine and Translational Research, 7(12), 3808-3817.
Barutta, F., Bellini, S., Canepa, S., Durazzo, M., Gruden, G. (2021). Novel biomarkers of diabetic kidney disease: current status and potential clinical application. Acta Diabetologica, 58(7), 819-830.?
Betsholtz, C., He, L., Takemoto, M., Norlin, J., Sun, Y., Patrakka, J., Tryggvason, K. (2007). The glomerular transcriptome and proteome. Nephron Experimental Nephrology, 106(2), e32-e36.?
Bouchard, J. (2021). Estimating Baseline Serum Creatinine for Assessing Acute Kidney Injury: Not a One Size Fits All Approach. Kidney International Reports, United States, 562–564.
Chida, S., Fujita, Y., Ogawa, A., Hayashi, A., Ichikawa, R., Kamata, Y., Shichiri, M. (2016). Levels of albuminuria and risk of developing macroalbuminuria in Type 2 diabetes: historical cohort study. Scientific Reports, 6(1), 1-8.?
Cole, J.B., Florez, J.C. (2020). Genetics of diabetes mellitus and diabetes complications. Nature Reviews Nephrology, 16(7), 377-390.?
El-ballat, M.A.F., Attia, M.H., Assem, A.A.A., Ellatif, A.E.I.A. (2023). Role Of Urinary Podocalyxin In Early Diagnosis Of Diabetic Kidney Disease. Al-Azhar International Medical Journal, 4(12), 55.
Ghorab, A.A.E., Diab, M.E., Abdelfattah, N.R., Elmenshawy, W.R. (2020). Study of Urinary Podocalyxin As an Early Biomarker in Diabetic Nephropathy. The Egyptian Journal of Hospital Medicine, 80(1), 627-632.?
Hara, M., Yamagata, K., Tomino, Y., Saito, A., Hirayama, Y., Ogasawara, S., Yan, K. (2012). Urinary podocalyxin is an early marker for podocyte injury in patients with diabetes: establishment of a highly sensitive ELISA to detect urinary podocalyxin. Diabetologia, 55(11), 2913-2919.?
Khalid, Z., Ali, A. (2022). Assessment of serum Podocalyxin as a biomarker for diabetic nephropathy in Type 2 diabetes patients in Duhok City”, Journal of Life and Bio Sciences Research, 3(02), 71 - 75.
Kostovska, I., Trajkovska, K.T., Cekovska, S., Topuzovska, S., Kavrakova, J.B., Spasovski, G., Labudovic, D. (2020). Role of urinary podocalyxin in early diagnosis of diabetic nephropathy. Romanian Journal of Internal Medicine, 58(4), 233-241.?
Lee, S.Y., Choi, M.E. (2015). Urinary biomarkers for early diabetic nephropathy: beyond albuminuria. Pediatric Nephrology, 30(7), 1063-1075.?
Li, Z., Xu, Y., Liu, X., Nie, Y., Zhao, Z. (2017). Urinary heme oxygenase?1 as a potential biomarker for early diabetic nephropathy. Nephrology, 22(1), 58-64.?
Miyamoto S & Shikata K (2021). Glycemic Control and Future Perspectives for Treatment. In: Wada T, Furuichi K & Kashihara N editors, Diabetic Kidney Disease. Singapore: Springer. 73–86.
Mohamed, A.H., Heibah, H.A., Ibrahim, H.E., Abdeen, H.M., Badawy, A. (2016). Urinary podocalyxin; a potential new marker for early diabetic nephropathy in Type 2 diabetes mellitus. Indian Journal of Applied Research, 6(1), 246-250
Porrini, E., Ruggenenti, P., Mogensen, C.E., Barlovic, D.P., Praga, M., Cruzado, J.M., ERA-EDTA Diabesity Working Group. (2015). Non-proteinuric pathways in loss of renal function in patients with Type 2 diabetes. Lancet Diabetes Endocrinol, 3(5), 382-391.?
Roden, M., Shulman, G.I. (2019). The integrative biology of Type 2 diabetes. Nature, 576(7785), 51-60.?
Shelbaya, S.E.D.A., Ibrahim, R.H., Sawirs, N.S., Ali, H.M. (2020). Study of The Podocalyxin as an early marker for diabetic nephropathy and its correlation with stages of diabetic nephropathy in a sample of Egyptian patients with T2DM. The Egyptian Journal of Hospital Medicine, 81(5), 2099-2102.?
Shoji, M., Kobayashi, K., Takemoto, M., Sato, Y., Yokote, K. (2016). Urinary podocalyxin levels were associated with urinary albumin levels among patients with diabetes. Biomarkers, 21(2), 164-167.?
?Xie, Y., Jin, D., Qiu, H., Lin, L., Sun, S., Li, D., Jia, M. (2021). Assessment of urinary podocalyxin as an alternative marker for urinary albumin creatinine ratio in early stage of diabetic kidney disease in older patients. Nefrologia, 42(6), 664-670
Ye, H., Bai, X., Gao, H., Li, L., Wu, C., Sun, X., Lu, Z. (2014). Urinary podocalyxin positive-element occurs in the early stage of diabetic nephropathy and is correlated with a clinical diagnosis of diabetic nephropathy. Journal of Diabetes and its Complications, 28(1), 96-100.?
Zhang, K., Zhang, W., Xia, F., Wang, N., Lu, Y., Sui. C., Wang, B. (2023). Obesity patterns, metabolic abnormality, and diabetic kidney disease in patients with Type 2 diabetes. Diabetes Metab Syndr Obes, 16, 3999–4011.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Copyright (c) 2025 Array